Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
Clinical trial NCT05370976 · TERMINATED
Trial details
- NCT number
- NCT05370976
- Sponsor
- University Hospital, Lille
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-13
- Primary completion
- 2023-08-24
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.